GPN00884 Eye Drops is an innovative drug for delaying the progression of myopia in children on a novel mechanism. Compared with low-concentration atropine eye drops, GPN00884 eye drops have no pupil dilation effect and do not cause adverse reactions such as photophobia and decreased accommodation. The dosing period of GPN00884 eye drops is not restricted, which can improve patient compliance.
China has the largest number of myopic people in the world. According to research findings of National Health Commission of the People’s Republic of China, the prevalence of myopia among Chinese adolescents is the highest in the world. In 2020, the overall myopia rate among Chinese adolescents will be 52.7%.
In delaying the progression of myopia in children, there is currently a lack of drugs in the country with clear efficacy and safety. Unmet clinical needs exist in this disease area. GPN00884 Eye Drops is expected to provide physicians and patients with a new clinical treatment option for delaying the progression of myopia in children.
The IND of GPN00884, a global innovative ophthalmic preparation of Grand Pharma approved by the National Medical Products Administration of China. The study is a randomized, double-blind, placebo-controlled, dose-escalation Phase I clinical trial to enroll 40 healthy subjects. The aim of the trial is to evaluate the safety, tolerability and pharmacokinetic profile of GPN00884 Eye Drops in healthy subjects after single and multiple administrations.
